Bayer Kogenate FS
Bayer HealthCare, Biological Products Division

Contact Search Press Sitemap  
HomePatients & CaregiversHealthcare ProfessionalsPrescribing Information
Prescribing Information
Important Safety Information
Bayer Links
Bayer Global
Living with Hemophilia
   General Conditions of Use
Privacy Statement
Imprint
  
 
  
 

Imprint

Edited and published by:
 
Bayer HealthCare,
Pharmaceuticals Division, Hematology/Cardiology
400 Morgan Lane
West Haven, CT, USA
06516
 
Phone: (+1)202-828-9733
Email: Website Administrator
 
© Copyright Bayer HealthCare

Last Updated: December 27, 2007







  

Kogenate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness, and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate® FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate® FS. For important safety and use information, please see the full prescribing information.

Please consult your health care provider prior to making any lifestyle changes. The images used on this site do not necessarily represent actual Hemophilia patients.